A Phase 2 Study of Xevinapant With Chemotherapy and Radiation Therapy After Surgery in People With Head and Neck Cancer


Full Title

A Phase II Trial of Xevinapant in Combination with Post-Operative Cisplatin and Radiotherapy for High Risk Head and Neck Cancer


Chemotherapy and radiation therapy (chemoradiation) are the usual treatments given to people with head and neck cancer after surgery. Researchers want to see if adding xevinapant to chemoradiation makes head and neck cancer treatment more effective. The people in this study have head and neck cancer that has a high chance of coming back or spreading.

Xevinapant blocks a protein that stops cancer cells from dying during chemoradiation treatment. Doctors hope that it makes cancer cells more vulnerable to the effects of chemoradiation. If you join this study, you will get cisplatin chemotherapy, radiation therapy, and xevinapant after cancer surgery. Cisplatin is given intravenously (by vein) and xevinapant is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have head and neck cancer that has a high chance of coming back or spreading (high risk).
  • Have head and neck cancer surgery within 10 weeks of signing up for the study.
  • Not have had prior radiation therapy to the head and neck.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Yao Yu’s office at 908-542-3427.




Phase II (phase 2)

Disease Status

Relapsed or Refractory


ClinicalTrials.gov ID